Antares Pharma (NASDAQ:ATRS) Coverage Initiated at StockNews.com


Stock analysts at StockNews.com assumed coverage on shares of Antares Pharma (NASDAQ:ATRS – Get Rating) in a report released on Saturday. The brokerage set a “sell” rating on the specialty pharmaceutical company’s stock.

A number of other research firms also recently commented on ATRS. Raymond James downgraded shares of Antares Pharma from a “strong-buy” rating to a “market perform” rating in a research report on Thursday, April 14th. LADENBURG THALM/SH SH downgraded shares of Antares Pharma from a “buy” rating to a “neutral” rating in a research report on Thursday, April 14th. Truist Financial downgraded shares of Antares Pharma from a “buy” rating to a “hold” rating and cut their target price for the company from $7.00 to $5.60 in a research report on Wednesday, April 13th. Piper Sandler downgraded shares of Antares Pharma from an “overweight” rating to a “neutral” rating and cut their target price for the company from $6.00 to $5.60 in a research report on Thursday, April 14th. Finally, HC Wainwright downgraded shares of Antares Pharma from a “buy” rating to a “neutral” rating and set a $5.60 target price on the stock. in a research report on Thursday, April 14th. One analyst has rated the stock with a sell rating and five have issued a hold rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average price target of $5.60.

Antares Pharma Stock Performance

ATRS stock opened at $5.59 on Friday. The company has a market capitalization of $955.06 million, a PE ratio of 23.29 and a beta of 1.15. Antares Pharma has a 12 month low of $3.11 and a 12 month high of $5.60. The firm’s 50-day moving average is $5.59 and its 200-day moving average is $4.71. The company has a debt-to-equity ratio of 0.10, a current ratio of 3.08 and a quick ratio of 2.87.

Antares Pharma (NASDAQ:ATRS – Get Rating) last posted its quarterly earnings results on Tuesday, May 10th. The specialty pharmaceutical company reported ($0.01) EPS for the quarter. The company had revenue of $41.56 million during the quarter, compared to analysts’ expectations of $44.01 million. Antares Pharma had a return on equity of 7.43% and a net margin of 21.90%. On average, research analysts anticipate that Antares Pharma will post 0.08 EPS for the current year.

Institutional Trading of Antares Pharma

Institutional investors have recently bought and sold shares of the stock. Shufro Rose & Co. LLC acquired a new stake in Antares Pharma in the 1st quarter worth approximately $41,000. Douglass Winthrop Advisors LLC acquired a new stake in Antares Pharma in the 1st quarter worth approximately $41,000. Mackenzie Financial Corp acquired a new stake in Antares Pharma in the 1st quarter worth approximately $45,000. Mercer Global Advisors Inc. ADV acquired a new stake in Antares Pharma in the 4th quarter worth approximately $46,000. Finally, GSA Capital Partners LLP acquired a new stake in Antares Pharma in the 1st quarter worth approximately $58,000. 50.41% of the stock is currently owned by institutional investors and hedge funds.

Antares Pharma Company Profile

(Get Rating)

Antares Pharma, Inc., a specialty pharmaceutical company, focuses primarily on the development and commercialization of pharmaceutical products and technologies that address patient needs in targeted therapeutic areas. It develops, manufactures, and commercializes novel therapeutic products using its drug delivery systems.

Featured Articles

Analyst Recommendations for Antares Pharma (NASDAQ:ATRS)



Receive News & Ratings for Antares Pharma Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Antares Pharma and related companies with MarketBeat.com’s FREE daily email newsletter.

.

Leave a Reply

Your email address will not be published.

Back to top button
DRAGONINKHOUSE